As consumer biotech enters its breakthrough decade, Geltor closed a fresh round of capital, which brings total funding to date to $137 million.WHO: Geltor is the leading biodesign company creating high-performance polypeptides for beauty, wellness, and longevity brands worldwide. Through AI-enabled design and precision fermentation, they produce clinically backed collagen, elastin, keratin, and more to deliver transformative consumer benefits at scale. Their biodesigned ingredients are backed by rigorous scientific research and manufactured globally. Founded in 2015 by Princeton classmates, Geltor partners with innovative brands seeking science-backed ingredients that drive measurable results and differentiated consumer experiences. Based in the San Francisco Bay Area, they serve customers across North America, Europe, Latin America, Asia, and Australia.WHY: The investment will be used to expand access to the biodesigned polypeptide portfolio to new geographies, bring new solutions to market for both topical and ingestible products, and push the limits of AI-enabled polypeptide design and biomanufacturing.IN THEIR OWN WORDS: "Consumer biotech has arrived, and our 75% revenue surge proves that Geltor’s products and Biodesigner AI platform are resonating. This funding lets us scale designer polypeptides for beauty, wellness, and longevity—profitably—while rolling out our disruptive ingestible collagen and a wave of new skin- and hair-care actives. My deepest thanks to the entire Geltor team, our board, and Andras Forgacs—once a competitor! now a partner—for seeing the opportunity ahead.